Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXSM OTCMKTS:CYDY NASDAQ:DCPH NASDAQ:GBT NASDAQ:PRLD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXSMAxsome Therapeutics$129.07+1.6%$120.78$75.56▼$139.13$6.43B0.52713,572 shs48,833 shsCYDYCytoDyn$0.26+4.1%$0.29$0.10▼$0.49$332.32M1.372.57 million shs55,375 shsDCPHDeciphera Pharmaceuticals$25.59$25.59$9.90▼$25.61$2.21B0.191.29 million shs600 shsGBTGlobal Blood Therapeutics$68.49$68.47$21.65▼$73.02$4.62B0.452.07 million shs74 shsPRLDPrelude Therapeutics$1.55+3.0%$1.24$0.61▼$1.91$87.45M1.28207,378 shs55,252 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXSMAxsome Therapeutics-2.05%+1.65%+7.50%+26.01%+37.63%CYDYCytoDyn-0.16%-2.69%-11.05%-14.53%+88.20%DCPHDeciphera Pharmaceuticals0.00%0.00%0.00%0.00%0.00%GBTGlobal Blood Therapeutics0.00%0.00%0.00%0.00%0.00%PRLDPrelude Therapeutics-5.06%+14.50%+45.63%+61.29%-8.54%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXSMAxsome Therapeutics$129.07+1.6%$120.78$75.56▼$139.13$6.43B0.52713,572 shs48,833 shsCYDYCytoDyn$0.26+4.1%$0.29$0.10▼$0.49$332.32M1.372.57 million shs55,375 shsDCPHDeciphera Pharmaceuticals$25.59$25.59$9.90▼$25.61$2.21B0.191.29 million shs600 shsGBTGlobal Blood Therapeutics$68.49$68.47$21.65▼$73.02$4.62B0.452.07 million shs74 shsPRLDPrelude Therapeutics$1.55+3.0%$1.24$0.61▼$1.91$87.45M1.28207,378 shs55,252 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXSMAxsome Therapeutics-2.05%+1.65%+7.50%+26.01%+37.63%CYDYCytoDyn-0.16%-2.69%-11.05%-14.53%+88.20%DCPHDeciphera Pharmaceuticals0.00%0.00%0.00%0.00%0.00%GBTGlobal Blood Therapeutics0.00%0.00%0.00%0.00%0.00%PRLDPrelude Therapeutics-5.06%+14.50%+45.63%+61.29%-8.54%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXSMAxsome Therapeutics 3.00Buy$178.2038.07% UpsideCYDYCytoDyn 0.00N/AN/AN/ADCPHDeciphera Pharmaceuticals 0.00N/AN/AN/AGBTGlobal Blood Therapeutics 0.00N/AN/AN/APRLDPrelude Therapeutics 2.33Hold$4.00158.90% UpsideCurrent Analyst Ratings BreakdownLatest AXSM, CYDY, DCPH, PRLD, and GBT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/20/2025AXSMAxsome TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$191.00 ➝ $194.0010/8/2025AXSMAxsome TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025PRLDPrelude TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/1/2025AXSMAxsome TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$179.009/30/2025AXSMAxsome TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$179.009/27/2025AXSMAxsome TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025PRLDPrelude TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/23/2025PRLDPrelude TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.009/3/2025AXSMAxsome TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/2/2025AXSMAxsome TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$163.008/18/2025PRLDPrelude TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$4.00 ➝ $3.00(Data available from 10/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXSMAxsome Therapeutics$385.69M16.70N/AN/A$1.18 per share109.38CYDYCytoDynN/AN/A$0.00 per share76.20($0.08) per shareN/ADCPHDeciphera Pharmaceuticals$174.91M12.65N/AN/A$4.38 per share5.84GBTGlobal Blood Therapeutics$194.75M23.73N/AN/A$3.05 per share22.46PRLDPrelude Therapeutics$7M12.49N/AN/A$2.39 per share0.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXSMAxsome Therapeutics-$287.22M-$5.07N/A45.77N/A-49.88%-283.22%-33.06%11/3/2025 (Estimated)CYDYCytoDyn$3.74M-$0.01N/A∞N/AN/AN/A-132.89%N/ADCPHDeciphera Pharmaceuticals-$194.94M-$2.21N/AN/AN/A-108.86%-52.42%-40.05%N/AGBTGlobal Blood Therapeutics-$303.09M-$5.01N/AN/AN/A-137.30%-170.37%-39.24%N/APRLDPrelude Therapeutics-$127.17M-$1.64N/AN/AN/AN/A-106.50%-79.07%11/5/2025 (Estimated)Latest AXSM, CYDY, DCPH, PRLD, and GBT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/5/2025Q3 2025PRLDPrelude Therapeutics-$0.41N/AN/AN/AN/AN/A11/3/2025Q3 2025AXSMAxsome Therapeutics-$0.80N/AN/AN/A$162.96 millionN/A8/14/2025Q2 2025PRLDPrelude Therapeutics-$0.45-$0.41+$0.04-$0.41N/AN/A8/4/2025Q2 2025AXSMAxsome Therapeutics-$1.00-$0.92+$0.08-$0.97$140.02 million$150.04 million7/25/2025Q4 2025CYDYCytoDynN/A-$0.01N/A-$0.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXSMAxsome TherapeuticsN/AN/AN/AN/AN/ACYDYCytoDynN/AN/AN/AN/AN/ADCPHDeciphera PharmaceuticalsN/AN/AN/AN/AN/AGBTGlobal Blood TherapeuticsN/AN/AN/AN/AN/APRLDPrelude TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXSMAxsome Therapeutics1.661.571.51CYDYCytoDynN/A0.190.19DCPHDeciphera PharmaceuticalsN/A4.193.94GBTGlobal Blood Therapeutics4.926.886.17PRLDPrelude TherapeuticsN/A3.683.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXSMAxsome Therapeutics81.49%CYDYCytoDyn5.06%DCPHDeciphera Pharmaceuticals70.96%GBTGlobal Blood TherapeuticsN/APRLDPrelude Therapeutics79.72%Insider OwnershipCompanyInsider OwnershipAXSMAxsome Therapeutics22.30%CYDYCytoDyn1.00%DCPHDeciphera Pharmaceuticals4.67%GBTGlobal Blood Therapeutics4.90%PRLDPrelude Therapeutics63.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXSMAxsome Therapeutics38049.90 million38.77 millionOptionableCYDYCytoDyn201.26 billion1.25 billionNot OptionableDCPHDeciphera Pharmaceuticals30086.48 million82.44 millionOptionableGBTGlobal Blood Therapeutics45767.48 million64.17 millionOptionablePRLDPrelude Therapeutics12056.60 million20.43 millionOptionableAXSM, CYDY, DCPH, PRLD, and GBT HeadlinesRecent News About These CompaniesPrelude Therapeutics (NASDAQ:PRLD) Upgraded at Wall Street ZenOctober 18, 2025 | marketbeat.comPrelude Therapeutics appoints Katina Dorton to board of directorsOctober 17, 2025 | msn.comPrelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of DirectorsOctober 17, 2025 | globenewswire.comPrelude Therapeutics (NASDAQ:PRLD) Shares Down 3.7% - Should You Sell?October 17, 2025 | marketbeat.comWeiss Ratings Reaffirms "Sell (D-)" Rating for Prelude Therapeutics (NASDAQ:PRLD)October 10, 2025 | marketbeat.comAnalysts Offer Predictions for PRLD Q3 EarningsSeptember 25, 2025 | marketbeat.comPrelude Therapeutics price target lowered to $3 from $4 at Citizens JMPAugust 19, 2025 | msn.comPrelude Cuts Q2 Losses and Costs 13%August 14, 2025 | aol.comAPrelude Therapeutics Pauses Intravenous SMARCA2 Degrader DevelopmentAugust 14, 2025 | msn.comPrelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 14, 2025 | globenewswire.comCan Prelude Therapeutics (NASDAQ:PRLD) Afford To Invest In Growth?August 11, 2025 | finance.yahoo.comPrelude Therapeutics Incorporated (PRLD) - Yahoo FinanceJune 25, 2025 | finance.yahoo.comPrelude Therapeutics Incorporated (PRLD) - Yahoo FinanceJune 25, 2025 | finance.yahoo.comPrelude Therapeutics to Present at Major Healthcare Conferences in June 2025June 3, 2025 | msn.comPrelude Therapeutics to Participate in Upcoming Healthcare ConferencesJune 2, 2025 | globenewswire.comPrelude Therapeutics’ SWOT analysis: clinical progress buoys stock amid challengesMay 28, 2025 | investing.comPathos AI secures $365M series D to fund trial of Novo Nordisk solid tumor drugMay 15, 2025 | fiercebiotech.comFPrelude Therapeutics Reports Q1 2025 Financial Results and Progress on Clinical ProgramsMay 10, 2025 | msn.comPrelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 6, 2025 | globenewswire.comPrelude Therapeutics to Host Fireside Chat at Citizens Life Sciences Conference 2025May 4, 2025 | msn.comPrelude Therapeutics to Participate in Citizens Life Sciences ConferenceMay 1, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAXSM, CYDY, DCPH, PRLD, and GBT Company DescriptionsAxsome Therapeutics NASDAQ:AXSM$129.06 +2.01 (+1.58%) As of 10:39 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.CytoDyn OTCMKTS:CYDY$0.26 +0.01 (+4.06%) As of 10:06 AM EasternCytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.Deciphera Pharmaceuticals NASDAQ:DCPHDeciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.Global Blood Therapeutics NASDAQ:GBTGlobal Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.Prelude Therapeutics NASDAQ:PRLD$1.54 +0.05 (+3.00%) As of 10:40 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 GM Posts Largest Gain Since the Pandemic: Shares Still Look Cheap 3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
